Chargement en cours...
Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
Chronic myelogenous leukemia (CML) requires the BCR/ABL tyrosine kinase for disease onset and maintenance. As a result, CML can be successfully treated with tyrosine kinase inhibitors (TKIs) such as imatinib. Most patients are maintained in a disease-suppressed state on daily TKI therapy for several...
Enregistré dans:
| Publié dans: | Mol Cell Oncol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4904890/ https://ncbi.nlm.nih.gov/pubmed/27308345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/23723548.2014.963450 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|